Parkwalk invests in UK companies that are commercialising research and technology that has spun out from a UK university or research-intensive institution. We believe this distinct asset class has the ability not only to generate attractive investment returns but also positive returns for UK plc, and broader society.
The technologies we back have normally been incubated over several years in their respective university, have been peer reviewed and are IP-protected, sitting at the cutting edge of innovation and creating solutions to real-world challenges. The current portfolio employs over 1,500 highly skilled people, and have over 2,000 patent families protecting their products and know-how.
The knowledge creation and trickle-down impact of the portfolio company work on society is impossible to quantify. But there have been leaps forward in med-tech, cleantech, AI / machine learning, disease diagnosis, interpretation of genomic data, gene therapies etc as a result of our investments.
The UK is a world leader in terms of R&D with approximately 1% of the world’s population but 16% of the mostly highly cited research papers
The UK is a university superpower with four of the 10 top-rated universities in the world, five of the top 20 and ten of the top 50
Adjusted for the size of their economies, the UK now exceeds the US in number of spinouts formed, disclosures of discoveries, patents and licenses
Government expenditure on Research & Development is set to expand to 2.4% of GDP as the UK looks to builds a new modern industrial base
Emerging asset class
We believe that after two decades of expansion in mobile and web technologies, we are now at the start of a new trend of deeper technologies that will impact all industries and create immense value
This has been heightened by the professionalisation of this asset class over the last 10-20 years as universities look to capitalise on the R&D and IP incubated within the research institutions for many years before emerging into a new company
We invest in UK companies that are commercialising technology that has spun out from a British university or research institution. The technology is well tested and IP-protected, sitting at the cutting edge of innovation and creating solutions to real-world challenges
We invest in global sectors of strategic importance to UK Plc, such as life sciences, AI and quantum computing, advanced materials, genomics, cleantech, future of mobility, medtech and big data
Parkwalk Funds invest in dynamic university spin-out companies seeking to commercialise intellectual property and technology. From investing in seed to later stage companies, we help fantastic management teams develop and build world-class successful businesses.
NeoPhore targets the dynamics of cancer neoantigen evolution and aims to make effective, well-tolerated medicines that will become a key part of the next-generation of cancer immunotherapies. NeoPhore’s drugs are designed to stimulate immunity directly at cancer’s core, by interfering with DNA repair and forcing cancer to continuously produce neoantigens that will be detected by
Cytoseek’s novel cell membrane augmentation technology enables the addition of new functionalities to cell therapies including tissue specific targeting and enhanced cell survivability. A spin-out from the University of Bristol, CytoSeek’s technology is based on the research of Dr Adam Perriman, who pioneered a new methodology for the rational design of synthetic artificial membrane-
MOA is a plant genetics company using its proprietary technology to generate potential candidates for use as herbicides. The herbicide market mirrors the antibiotic market, in that there have been few new molecules developed in recent years and resistance is developing to those products on the market.